Shionogi to Steadily Promote PIII Trial for COVID Pill after Approval Setback
To read the full story
Related Article
- Japan Govt to Purchase Another 1 Million Courses of Xocova
December 14, 2022
- Japan Should Hone Emergency Approval Scheme Based on Xocova Example
November 28, 2022
- Shionogi Chief Defends Xocova Data, Eager to Prove Benefits in Clinical Settings
November 25, 2022
- Japan Grants 1st Emergency Approval to Shionogi COVID Pill Xocova
November 24, 2022
- Japan Again Takes Pass on Emergency Approval for Shionogi’s COVID Pill as Panels Nix Presumed Efficacy
July 21, 2022
BUSINESS
- Astellas Snags Rights to Sangamo’s AVV Capsid for Neurological Diseases
December 20, 2024
- Xocova to Be Re-Filed in South Korea with Additional Data
December 20, 2024
- JCR Commences PIII Study for Once-Weekly Growth Hormone Therapy
December 20, 2024
- Insomnia Med Quviviq Now Available in Japan: Nxera/Shionogi
December 20, 2024
- PeptiDream Gets Milestone from Novartis on PI Launch
December 20, 2024
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…